Immunoprotective properties of primary sertoli cells in mice: Potential functional pathways that confer immune privilege

Biology of Reproduction

Volumn 86, Issue 1, 2012, Pages

  Doyle, Timothy J ^a   Kaur, Gurvinder ^b   Putrevu, Saroja M ^b   Dyson, Emily L ^b   Dyson, Mathew ^b   McCunniff, William T ^b   Pasham, Mithun R ^b   Kim, Kwan Hee ^a   Dufour, Jannette M ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Immune privilege; Microarray; MSC 1 cells; Sertoli cells; Testis; Transplantation

Indexed keywords

CELL ANTIBODY; PROSTANOID;

ACTIN POLYMERIZATION; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL JUNCTION; CELL PROTECTION; CELL SURVIVAL; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; GENE EXPRESSION PROFILING; GRAFT SURVIVAL; IMMUNOGENETICS; KIDNEY CAPSULE; LEUKOCYTE MIGRATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERTOLI CELL; TESTIS; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL ADHESION; CELL LINE; GENE EXPRESSION REGULATION; IMMUNOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIGHT JUNCTION; TRANSPLANTATION;

MUS; RODENTIA;

ADHERENS JUNCTIONS; ANIMALS; APOPTOSIS; CELL ADHESION; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERTOLI CELLS; TIGHT JUNCTIONS;

EID: 84856944249     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.110.089425     Document Type: Article

References (63)

1. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol 1977; 25:1-54.
2. Whitmore WF III, Karsh L, Gittes RF. The role of germinal epithelium and spermatogenesis in the privileged survival of intratesticular grafts. J Urol 1985; 134:782-786.
3. Cameron DF, Whittington K, Schultz RE, Selawry HP. Successful islet/ abdominal testis transplantation does not require Leydig cells. Transplantation 1990; 50:649-653.
4. Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 1993; 2:123-129.
5. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46:317-322.
6. Sanberg PR, Borlongan CV, Saporta S, Cameron DF. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nat Biotechnol 1996; 14:1692-1695.
7. Yang H, Wright JR Jr. Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation 1999; 67:815-820.
8. Dufour JM, Rajotte RV, Kin T, Korbutt GS. Immunoprotection of rat islet xenografts by cotransplantation with sertoli cells and a single injection of antilymphocyte serum. Transplantation 2003; 75:1594-1596.
9. Dufour JM, Dass B, Halley KR, Korbutt GS, Dixon DE, Rajotte RV. Sertoli cell line lacks the immunoprotective properties associated with primary Sertoli cells. Cell Transplant 2008; 17:525-534.
10. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant 2010; 15:486-491.
11. Dufour JM, Hamilton M, Rajotte RV, Korbutt GS. Neonatal porcine Sertoli cells inhibit human natural antibody-mediated lysis. Biol Reprod 2005; 72:1224-1231.
12. Mital P, Kaur G, Dufour JM. Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation feasible. Reproduction 2010; 139:495-504.
13. Meinhardt A, Hedger MP. Immunological, paracrine and endocrine aspects of testicular immune privilege. Mol Cell Endocrinol 2011; 335:60-68.
14. Hedger MP, Meinhardt A. Cytokines and the immune-testicular axis. J Reprod Immunol 2003; 58:1-26.
15. Guazzone VA, Jacobo P, Theas MS, Lustig L. Cytokines and chemokines in testicular inflammation: a brief review. Microsc Res Tech 2009; 72:620-628.
16. Cobbold SP. Regulatory T cells and transplantation tolerance. J Nephrol 2008; 21:485-496.
17. Hegde S, Pahne J, Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004; 18:1439-1441.
18. Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, Kakishita E. Elevated interleukin (IL)-18 levels during acute graft-versushost disease after allogeneic bone marrow transplantation. Br J Haematol 2000; 109:652-657.
19. Peschon JJ, Behringer RR, Cate RL, Harwood KA, Idzerda RL, Brinster RL, Palmiter RD. Directed expression of an oncogene to Sertoli cells in transgenic mice using Mullerian inhibiting substance regulatory sequences. Mol Endocrinol 1992; 6:1403-1411.
20. Dufour JM, Lord SJ, Kin T, Rayat GR, Dixon DE, Bleackley RC, Korbutt GS, Rajotte RV. Comparison of successful and unsuccessful islet/Sertoli cell cotransplant grafts in streptozotocin-induced diabetic mice. Cell Transplant 2008; 16:1029-1038.
21. Dufour JM, Hemendinger R, Halberstadt CR, Gores P, Emerich DF, Korbutt GS, Rajotte RV. Genetically engineered Sertoli cells are able to survive allogeneic transplantation. Gene Ther 2004; 11:694-700.
22. Johnston DS, Wright WW, Dicandeloro P, Wilson E, Kopf GS, Jelinsky SA. Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli cells. Proc Natl Acad Sci U S A 2008; 105:8315-8320.
23. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res 2007; 17:1537-1545.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
25. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-1108.
26. Hales KH, Diemer T, Ginde S, Shankar BK, Roberts M, Bosmann HB, Hales DB. Diametric effects of bacterial endotoxin lipopolysaccharide on adrenal and Leydig cell steroidogenic acute regulatory protein. Endocrinology 2000; 141:4000-4012.
27. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993; 119:1329-1341.
28. Ortutay C, Vihinen M. Immunome knowledge base (IKB): an integrated service for immunome research. BMC Immunol 2009; 10:3.
29. Friedl P, Weigelin B. Interstitial leukocyte migration and immune function. Nat Immunol 2008; 9:960-969.
30. Muller WA. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 2011; 6:323-344.
31. Riccioli A, Filippini A, De Cesaris P, Barbacci E, Stefanini M, Starace G, Ziparo E. Inflammatory mediators increase surface expression of integrin ligands, adhesion to lymphocytes, and secretion of interleukin 6 in mouse Sertoli cells. Proc Natl Acad Sci U S A 1995; 92:5808-5812.
32. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C, Shi Y. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184:2321-2328.
33. van Buul JD, van Alphen FP, Hordijk PL. The presence of alpha-catenin in the VE-cadherin complex is required for efficient transendothelial migration of leukocytes. Int J Biol Sci 2009; 5:695-705.
34. Johnson-Leger CA, Aurrand-Lions M, Beltraminelli N, Fasel N, Imhof BA. Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration. Blood 2002; 100:2479-2486.
35. Kometani K, Ishida D, Hattori M, Minato N. Rap1 and SPA-1 in hematologic malignancy. Trends Mol Med 2004; 10:401-408.
36. Katayama K, Melendez J, Baumann JM, Leslie JR, Chauhan BK, Nemkul N, Lang RA, Kuan CY, Zheng Y, Yoshida Y. Loss of RhoA in neural progenitor cells causes the disruption of adherens junctions and hyperproliferation. Proc Natl Acad Sci U S A 2011; 108:7607-7612.
37. Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc Res 2010; 87:243-253.
38. Meng J, Greenlee AR, Taub CJ, Braun RE. Sertoli Cell-specific deletion of the androgen receptor compromises testicular immune privilege in mice. Biol Reprod 2011; 85:254-260.
39. Ye P, Nadkarni MA, Simonian M, Hunter N. CD24 regulated gene expression and distribution of tight junction proteins is associated with altered barrier function in oral epithelial monolayers. BMC Cell Biol 2009; 10:2.
40. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323:1722-1725.
41. Li O, Chang X, Zhang H, Kocak E, Ding C, Zheng P, Liu Y. Massive and destructive T cell response to homeostatic cue in CD24-deficient lymphopenic hosts. J Exp Med 2006; 203:1713-1720.
42. Wallgren AC, Karlsson-Parra A, Korsgren O. The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 1995; 60:594-601.
43. Volpe F, Clatworthy J, Kaptein A, Maschera B, Griffin AM, Ray K. The IL1 receptor accessory protein is responsible for the recruitment of the interleukin-1 receptor associated kinase to the IL1/IL1 receptor I complex. FEBS Lett 1997; 419:41-44.
44. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42:358-364.
45. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002; 39:531-536.
46. Boulanger MJ, Garcia KC. Shared cytokine signaling receptors: structural insights from the gp130 system. Adv Protein Chem 2004; 68:107-146.
47. Suarez-Pinzon W, Korbutt GS, Power R, Hooton J, Rajotte RV, Rabinovitch A. Testicular sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice by a transforming growth factorbeta1-dependent mechanism. Diabetes 2000; 49:1810-1818.
48. Zenclussen AC, Gerlof K, Zenclussen ML, Ritschel S, Zambon Bertoja A, Fest S, Hontsu S, Ueha S, Matsushima K, Leber J, Volk HD. Regulatory T cells induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur J Immunol 2006; 36:82-94.
49. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005; 46:908-919.
50. DeRosa DC, Ryan PJ, Okragly A, Witcher DR, Benschop RJ. Tumorderived death receptor 6 modulates dendritic cell development. Cancer Immunol Immunother 2008; 57:777-787.
51. Ringwood L, Li L. The involvement of the interleukin-1 receptorassociated kinases (IRAKs) in cellular signaling networks controlling inflammation. Cytokine 2008; 42:1-7.
52. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
53. Ledford JG, Kovarova M, Koller BH. Impaired host defense in mice lacking ONZIN. J Immunol 2007; 178:5132-5143.
54. Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 2006; 177:3799-3805.
55. Gilroy DW, Newson J, Sawmynaden P, Willoughby DA, Croxtall JD. A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J 2004; 18:489-498.
56. Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 2009; 32:22-28.
57. McManus LM, Pinckard RN. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 2000; 11:240-258.
58. Powell WS. A novel PGD(2) receptor expressed in eosinophils. Prostaglandins Leukot Essent Fatty Acids 2003; 69:179-185.
59. Murray-Rust TA, Kerr FK, Thomas AR, Wu T, Yongqing T, Ong PC, Quinsey NS, Whisstock JC, Wagenaar-Bos IC, Freeman C, Pike RN. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1. Biochem J 2009; 422:295-303.
60. Esposito A, Suedekum B, Liu J, An F, Lass J, Strainic MG, Lin F, Heeger P, Medof ME. Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant 2010; 10:527-534.
61. Lin F, Fukuoka Y, Spicer A, Ohta R, Okada N, Harris CL, Emancipator SN, Medof ME. Tissue distribution of products of the mouse decayaccelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001; 104:215-225.
62. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:345-357.
63. Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A 1989; 86:7123-7127.